Search Result

Results for "

plaque macrophages

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Amyloid-β (1) Apoptosis (2) Fluorescent Dye (1) Formyl Peptide Receptor (FPR) (1) GCGR (2) Interleukin Related (1) Isotope-Labeled Compounds (1) JNK (2) MEK (2) MMP (3) Prostaglandin Receptor (1) Pyroptosis (1) Reactive Oxygen Species (ROS) (1)
By Research Areas:	Cardiovascular Disease (4) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (3)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Isotope-Labeled Compounds

Targets Recommended: Macrophage migration inhibitory factor (MIF)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113870

6-NBDG	Fluorescent Dye	Others
6-NBDG is a fluorescent glucose analogue, it can be used for fluorescence imaging and monitoring glucose transport and uptake. 6-NBDG can be used as a fluorescent probe for detecting macrophage-rich atherosclerotic plaques .

HY-135517

RXP470.1 RXP-470	MMP	Cardiovascular Disease
RXP470.1 (RXP-470) is a potent, selective MMP-12 inhibitor with a K_i of 0.2 nM against human MMP-12. RXP470.1 is 2 to 4 orders of magnitude less potent against other MMPs. RXP470.1 significantly reduces atherosclerotic plaque cross-sectional area in mouse. RXP470.1 results in less complex plaques with increased smooth muscle cell:macrophage ratio, less macrophage apoptosis, increased cap thickness, smaller necrotic cores, and decreased incidence of calcification .

HY-P0119

Lixisenatide 2 Publications Verification	GCGR MEK Akt MMP JNK	Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^−/− Irs ^2+/− mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

HY-173591

T0080	Formyl Peptide Receptor (FPR) Apoptosis Reactive Oxygen Species (ROS) Interleukin Related	Cardiovascular Disease
T0080 is a FPR-1 antagonist. T0080 reduces the cell apoptosis, inhibits ROS production and pro-inflammatory cytokines (TNF-α and IL-1β) from plaque macrophages, which attenuates atherosclerotic progression in ApoE ^−/− mice .

HY-P11289

Intermedin1-53 (Human)	Apoptosis	Cardiovascular Disease
Intermedin1-53 (Human) is a 53-aa human calcitonin family peptide that reduces the vulnerability of atherosclerotic plaques by inhibiting CHOP-mediated macrophage apoptosis and inflammasome .

HY-173234

GI-Y2	Pyroptosis	Cardiovascular Disease
GI-Y2 is an inhibitor of GSDMD and can inhibit Pyroptosis of macrophages induced by oxidized low-density lipoprotein (ox-LDL). In vivo, GI-Y2 can dose-dependently reduce atherosclerotic plaques in ApoE-/- mice and decrease the lesion size and fibrosis degree of the aortic root. GI-Y2 is expected to be used in the research of pyroptosis and cardiovascular diseases, such as atherosclerosis .

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA	Isotope-Labeled Compounds GCGR MEK Akt MMP JNK	Neurological Disease
Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^?/? Irs ^2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

HY-176293

EP2 receptor antagonist-3	Prostaglandin Receptor Amyloid-β	Neurological Disease
EP2 receptor antagonist-3 is a selective EP2 receptor antagonist (IC₅₀: 8 nM in hEP2 SPA assay, 50 nM in hEP2 cAMP assay). EP2 receptor antagonist-3 increases the macrophage-mediated clearance of Amyloid-β plaques. EP2 receptor antagonist-3 shows moderate clearance and good exposure in CD-1 mice and good CNS exposure in mice and rats. EP2 receptor antagonist-3 can be used for the study of alzheimer’s diseases .

Cat. No.	Product Name	Type

HY-113870

6-NBDG	Fluorescent Dyes/Probes
6-NBDG is a fluorescent glucose analogue, it can be used for fluorescence imaging and monitoring glucose transport and uptake. 6-NBDG can be used as a fluorescent probe for detecting macrophage-rich atherosclerotic plaques .

Cat. No.	Product Name	Target	Research Area

HY-P0119

Lixisenatide 2 Publications Verification	GCGR MEK Akt MMP JNK	Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^−/− Irs ^2+/− mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

HY-P11289

Intermedin1-53 (Human)	Apoptosis	Cardiovascular Disease
Intermedin1-53 (Human) is a 53-aa human calcitonin family peptide that reduces the vulnerability of atherosclerotic plaques by inhibiting CHOP-mediated macrophage apoptosis and inflammasome .

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA	Isotope-Labeled Compounds GCGR MEK Akt MMP JNK	Neurological Disease
Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^?/? Irs ^2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

Cat. No.	Product Name	Chemical Structure

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA
Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^?/? Irs ^2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

Lixisenatide (Leu-13C6,15N) TFA

Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^?/? Irs ^2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.